Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2517496 | 0.86 | PPARA (0.49) | PPARAPTPN1PPARGKDM4EL3MBTL1 | |
| SCHEMBL20861471 | 0.86 | PPARA (0.53) | PPARAPTPN1PPARGKDM4EL3MBTL1 | |
| SCHEMBL9831925 | 0.85 | PTPN1 (0.51) | PPARAPTPN1PPARGKDM4EL3MBTL1 | |
| SCHEMBL1049514 | 0.85 | PPARA (0.48) | PPARAPTPN1PPARGKDM4EL3MBTL1 | |
| SCHEMBL4890697 | 0.82 | PPARA (0.54) | PPARAPTPN1PPARGKDM4EL3MBTL1 | |
| SCHEMBL5759578 | 0.81 | KDM4E (0.47) | PPARAPTPN1PPARGKDM4EL3MBTL1 | |
| SCHEMBL5761603 | 0.80 | KDM4E (0.70) | PPARAPTPN1PPARGKDM4EIKBKB | |
| SCHEMBL4484960 | 0.80 | PPARA (0.58) | PPARAPTPN1PPARGKDM4EL3MBTL1 | |
| SCHEMBL10721010 | 0.80 | PTPN1 (0.46) | PPARAPTPN1PPARGKDM4EL3MBTL1 | |
| SCHEMBL14431360 | 0.80 | TARBP2 (0.50) | PPARAPPARGKDM4EPDE4BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528160-B2 | Fused heterocyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7259175-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2007-08-21 | — | — | US | disclosed |
| EP-1480640-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1480640-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7153878-B2 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| US-20060166983-A1 | Indole derivatives as ppar modulators | ELI LILLY AND COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060084663-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY, PATENT DIVISION (US) | 2006-04-20 | — | — | US | disclosed |
| EP-1581491-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581521-A1 | FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | ELILILLY AND COMPANY | 2005-05-19 | — | — | US | disclosed |
| EP-1480642-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1480640-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004092131-A1 | INDOLE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004063190-A1 | FUSED HETEROCYCLIC DERIVATES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003072102-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003072100-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166983-A1 | Indole derivatives as ppar modulators | PPARA, PPARD, PPARG | PPARA 1/4885PTPN1 2276/4885PPARG 3/4885 |
| US-20050107449-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PPARA 2/4885PTPN1 1071/4885PPARG 1/4885 |
| US-20060217374-A1 | Fused heterocyclic derivates as ppar modulators | PPARG, PPARA, PPARD | PPARA 2/4885PTPN1 2288/4885PPARG 1/4885 |
| US-20060084663-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | PPARA 2/4885PTPN1 1032/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.